1. Home
  2. THRY vs HURA Comparison

THRY vs HURA Comparison

Compare THRY & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Thryv Holdings Inc.

THRY

Thryv Holdings Inc.

HOLD

Current Price

$3.88

Market Cap

170.3M

Sector

Industrials

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.13

Market Cap

160.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
THRY
HURA
Founded
2012
2009
Country
United States
United States
Employees
N/A
22
Industry
Industrial Machinery/Components
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
170.3M
160.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
THRY
HURA
Price
$3.88
$2.13
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$9.33
$9.50
AVG Volume (30 Days)
532.0K
581.0K
Earning Date
04-30-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
100.50
N/A
EPS
0.10
N/A
Revenue
$785,015,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$37.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$0.41
52 Week High
$14.28
$3.90

Technical Indicators

Market Signals
Indicator
THRY
HURA
Relative Strength Index (RSI) 50.66 40.23
Support Level $3.27 $1.82
Resistance Level $4.14 $2.20
Average True Range (ATR) 0.25 0.15
MACD -0.05 -0.02
Stochastic Oscillator 48.77 1.00

Price Performance

Historical Comparison
THRY
HURA

About THRY Thryv Holdings Inc.

Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: